Insmed Inc
Company Profile
Business description
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Contact
700 US Highway 202/206
BridgewaterNJ08807
USAT: +1 908 977-9900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,664
Stocks News & Analysis
stocks
Cheap e-commerce share continues sales momentum
stocks
Chart of the Week: Booming mined commodity prices see little value on offer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,886.40 | 1.70 | 0.02% |
| CAC 40 | 8,207.89 | 34.78 | 0.43% |
| DAX 40 | 25,177.80 | 7.09 | -0.03% |
| Dow JONES (US) | 50,644.28 | 182.60 | 0.36% |
| FTSE 100 | 10,505.01 | 13.62 | 0.13% |
| HKSE | 24,959.87 | 368.36 | -1.45% |
| NASDAQ | 26,674.73 | 18.55 | 0.07% |
| Nikkei 225 | 65,108.61 | 109.20 | 0.17% |
| NZX 50 Index | 13,255.05 | 27.24 | 0.21% |
| S&P 500 | 7,520.36 | 1.24 | 0.02% |
| S&P/ASX 200 | 8,659.10 | 4.60 | 0.05% |
| SSE Composite Index | 4,076.47 | 17.26 | -0.42% |